GlassScriptPhysician profile
Arshad H Malik
NPI 1225090269
$10,715.87
in general payments reported to CMS, 2019-2025
49 companies · $2,017 in 2025
The $2,017 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,280 · 2020: $1,050 · 2021: $754 · 2022: $1,444 · 2023: $2,099 · 2024: $2,072 · 2025: $2,017.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,172 · Education: $16.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,172.40 |
| Education | $16.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,325.54 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $875.01 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $867.25 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $613.10 | 2020-2025 | Stelara, Tremfya, Simponi |
| Celgene Corporation | $555.82 | 2021-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $299.33 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $220.30 | 2020-2024 | Dificid, Zerbaxa, Recarbrio |
| Regeneron Healthcare Solutions, INC. | $215.94 | 2022-2025 | Dupixent |
| Medtronic, INC. | $211.81 | 2022-2024 | Pillcam, Gi Genius |
| Pfizer INC. | $194.17 | 2019-2025 | |
| Genzyme Corporation | $190.17 | 2022-2025 | |
| Madrigal Pharmaceuticals | $182.24 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $181.03 | 2023-2025 | Omvoh |
| Ardelyx, INC. | $179.18 | 2023-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $120.95 | 2019-2023 | Clenpiq, Rebyota |
Show all 48 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$29,296.74 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arshad Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.